EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chemotherapy-Induced Hematological Toxicity in Patients with Renal or Hepatic Impairment

Kelly Nies iD, Robin Vernooij iD, Lot Devriese, Jan-Hendrik Venhuizen, Maarten Ten Berg iD, Christina Swart, Laureen Lammers iD, Saskia Haitjema iD

Pharmaceutics · 30.09.2025 · 17 (10) · 1280

DOI: 10.3390/pharmaceutics17101280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.09.2025. Verfasst von Kelly Nies und 7 weiteren Autor:innen. Beteiligte Einrichtung: Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Holland, Health~Holland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Hematological toxicities (i.e., neutropenia, thrombocytopenia, and anemia), are common chemotherapy complications and may be exacerbated by renal or hepatic impairment due to altered drug exposure. This study assessed the association between renal and hepatic impairment and hematologic toxicities during chemotherapy in routine clinical practice.

Methods

A single-center retrospective cohort study using the Utrecht Patient Oriented Database (UPOD) identified all chemotherapy administrations at the University Medical Centre Utrecht between 2011 and 2024. Regimens administered in ≥10 patients and ≥5 renally (GFR < 60 mL/min) or hepatically (bilirubin or AST > 1× ULN) impaired patients were included in descriptive analyses. Cox proportional hazards models estimated associations between organ impairment and grade ≥ 3 hematologic toxicities for regimens with ≥10 events per toxicity endpoint.

Results

Overall, 4489 patients were included in renal analyses and 6218 in hepatic analyses, with smaller endpoint-specific subgroups for survival analyses. Renal impairment was associated with grade ≥ 3 neutropenia (HR: 1.43 [95% CI: 1.18–1.73]), thrombocytopenia (HR: 1.46 [95% CI: 1.15–1.86], and anemia (HR: 1.66 [1.27–2.16]). Hepatic impairment was similarly associated with neutropenia (HR: 1.25 [95% CI: 1.11–1.40]), thrombocytopenia (HR: 1.33 [95% CI: 1.13–1.57]), and anemia (HR: 1.62 [95% CI: 1.34–1.95]). Cyclophosphamide (pro-drug) regimens showed higher toxicity risk in renally impaired patients and reduced risk in hepatically impaired patients. Etoposide, melphalan and methotrexate were associated with increased toxicity in hepatically impaired patients.

Conclusions

Renal and hepatic impairment significantly increase chemotherapy-induced hematologic toxicity. Several high-risk chemotherapy regimens were identified; however, larger multi-center datasets are needed to refine dosing guidance based on renal and hepatic function.

Schlagwörter

Stichwörter der Autor:innen

chemotherapyhematological toxicityhepatic impairmentrenal impairment

Autor:innen und Institutionen

  • Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.
  • Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.
  • Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.
  • Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.
  • Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands.

ORCID-Profile: Kelly Nies, Robin Vernooij, Maarten Ten Berg, Laureen Lammers, Saskia Haitjema

Förderung

  • Health Holland
  • Health~Holland

Zitieren

APA

Nies, K., Vernooij, R., Devriese, L., Venhuizen, J. H., Ten Berg, M., Swart, C., Lammers, L., & Haitjema, S. (2025). Chemotherapy-Induced Hematological Toxicity in Patients with Renal or Hepatic Impairment. Pharmaceutics, 17(10), 1280. https://doi.org/10.3390/pharmaceutics17101280

Vancouver

Nies K, Vernooij R, Devriese L, Venhuizen JH, Ten Berg M, Swart C, et al. Chemotherapy-Induced Hematological Toxicity in Patients with Renal or Hepatic Impairment. Pharmaceutics. 2025;17(10):1280. doi:10.3390/pharmaceutics17101280

BibTeX
@article{Nies2025,
  author = {Nies, Kelly and Vernooij, Robin and Devriese, Lot and Venhuizen, Jan-Hendrik and Ten Berg, Maarten and Swart, Christina and Lammers, Laureen and Haitjema, Saskia},
  title = {Chemotherapy-Induced Hematological Toxicity in Patients with Renal or Hepatic Impairment},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {1280},
  doi = {10.3390/pharmaceutics17101280}
}
Kostenlos starten →